Date Title Description PDF
25 Apr 2023 On business and financial situation ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) Download
21 Feb 2023 On business and financial situation The Company releases the full year 2022 financial results presentation. Download
21 Feb 2023 On business and financial situation The Company releases the press release related to the full year 2022 financial results. Download
21 Feb 2023 On business and financial situation The company releases the Integrated Report for the year 2022 Download
21 Feb 2023 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download

Pages

Date Title Description PDF
25 Feb 2025 Annual Financial Reports and Audit Reports The Company submits the 2024 Annual Financial Report  Download
25 Feb 2025 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2024 annual report regarding remuneration of the members of the Board of Directors Download
07 Jan 2025 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the fourth quarter of 2024 Download
07 Nov 2024 On P&L A correction to the English version of a document is reported. Download
03 Oct 2024 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the third quarter of 2024 Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages